Arvinas (NASDAQ:ARVN) CEO Sells $19,969.36 in Stock

Arvinas, Inc. (NASDAQ:ARVN) CEO Randy Teel sold 2,209 shares of the stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $9.04, for a total value of $19,969.36. Following the sale, the chief executive officer owned 285,009 shares of the company’s stock, valued at approximately $2,576,481.36. The trade was a 0.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Randy Teel also recently made the following trade(s):

• On Monday, May 11th, Randy Teel sold 9,657 shares of Arvinas stock. The stock was sold at an average price of $9.94, for a total value of $95,990.58.
• On Monday, February 23rd, Randy Teel sold 4,786 shares of Arvinas stock. The stock was sold at an average price of $12.16, for a total value of $58,197.76.

Arvinas Stock Down 0.1%

Arvinas stock traded down $0.01 during trading hours on Friday, reaching $9.09. 778,275 shares of the company’s stock were exchanged, compared to its average volume of 864,744. The firm has a market capitalization of $586.49 million, a PE ratio of -2.74 and a beta of 1.79. The firm’s 50 day simple moving average is $10.59 and its 200 day simple moving average is $11.66. Arvinas, Inc. has a twelve month low of $6.05 and a twelve month high of $14.51.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.95) by $0.05. The company had revenue of $15.60 million for the quarter, compared to analysts’ expectations of $16.61 million. Arvinas had a negative net margin of 247.54% and a negative return on equity of 44.38%. The business’s revenue was down 91.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.14 EPS. Analysts anticipate that Arvinas, Inc. will post -2.85 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Quantinno Capital Management LP grew its stake in Arvinas by 12.5% in the 1st quarter. Quantinno Capital Management LP now owns 74,540 shares of the company’s stock valued at $790,000 after buying an additional 8,295 shares in the last quarter. Weiss Asset Management LP purchased a new position in Arvinas in the 1st quarter valued at approximately $385,000. Public Employees Retirement System of Ohio grew its stake in Arvinas by 876.1% in the 1st quarter. Public Employees Retirement System of Ohio now owns 97,611 shares of the company’s stock valued at $1,035,000 after buying an additional 87,611 shares in the last quarter. Sei Investments Co. grew its stake in Arvinas by 160.7% in the 1st quarter. Sei Investments Co. now owns 78,587 shares of the company’s stock valued at $833,000 after buying an additional 48,444 shares in the last quarter. Finally, Globeflex Capital L P grew its stake in Arvinas by 433.2% in the 1st quarter. Globeflex Capital L P now owns 59,331 shares of the company’s stock valued at $629,000 after buying an additional 48,203 shares in the last quarter. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on ARVN. Zacks Research cut shares of Arvinas from a “hold” rating to a “strong sell” rating in a report on Monday, April 27th. Barclays lifted their price target on shares of Arvinas from $18.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, May 13th. BTIG Research lifted their price target on shares of Arvinas from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Piper Sandler reaffirmed an “overweight” rating and issued a $20.00 price target (up from $16.00) on shares of Arvinas in a report on Wednesday, February 25th. Finally, Weiss Ratings cut shares of Arvinas from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. Eight research analysts have rated the stock with a Buy rating, three have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $14.69.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.